Table 1 The characteristics of people eligible for analysis by treatment choice in the follow-up year
Continue (n = 8939) | Switch (n = 1119) | Add (n = 2110) | p | |
|---|---|---|---|---|
Age at diagnosis (years) | 57.4 (10.5) | 54.8 (10.2) | 55.3 (10.3) | < 0.001 |
Female [n (%)] | 3544 (39.6) | 472 (42.2) | 865 (41.0) | 0.175 |
BMI (kg/m2) | 31.5 (6.03) | 33.9 (6.6) | 33.5 (6.5) | < 0.001 |
eGFR (ml/min) | 77.0 (19.1) | 83.4 (17.6) | 82.81 (18.3) | < 0.001 |
Diabetes duration (years) | 6.2 (4.7) | 5.5 (4.3) | 4.9 (4.1) | < 0.001 |
HbA1c (mmol/mol) before first new medication | 69.4 (10.6) | 71.9 (11.1) | 72.6 (11.8) | < 0.001 |
First new medication class [n (%)] | < 0.001 | |||
Metformin | 1951 (21.8) | 109 (9.7) | 302 (14.3) | |
Sulfonylureas | 2594 (29.0) | 203 (18.1) | 772 (36.6) | |
TZDs | 2485 (27.8) | 227 (20.3) | 335 (15.9) | |
Acarbose | 127 (1.4) | 24 (2.1) | 18 (0.9) | |
Glinides | 101 (1.1) | 51 (4.6) | 22 (1.0) | |
DPP4 inhibitors | 1514 (16.9) | 447 (39.9) | 597 (28.3) | |
SGLT2 inhibitors | 101 (1.1) | 42 (3.8) | 40 (1.9) | |
GLP1 analogues | 66 (0.7) | 16 (1.4) | 24 (1.1) | |
HbA1c (mmol/mol) 6 months after first new medication | 71.5 (14.4) | 76.2 (15.4) | 77.8 (15.4) | < 0.001 |
Change in HbA1c at 6 months (mmol/mol)* | 2.1 (8.3) | 4.3 (9.8) | 5.2 (10.0) | < 0.001 |
Second new medication class [n (%)] | < 0.001 | |||
Metformin | N/A | 25 (2.2) | 62 (2.9) | |
Sulfonylureas | N/A | 243 (21.7) | 627 (29.7) | |
TZDs | N/A | 248 (22.2) | 621 (29.4) | |
Acarbose | N/A | 13 (1.2) | 57 (2.7) | |
Glinides | N/A | 34 (3.0) | 19 (0.9) | |
DPP4 inhibitors | N/A | 199 (17.8) | 455 (21.6) | |
SGLT2 inhibitors | N/A | 131 (11.7) | 143 (6.8) | |
GLP1 analogues | N/A | 226 (20.2) | 126 (6.0) |